WO1994012219A2 - Modified insulin-like growth factors - Google Patents
Modified insulin-like growth factors Download PDFInfo
- Publication number
- WO1994012219A2 WO1994012219A2 PCT/US1993/011458 US9311458W WO9412219A2 WO 1994012219 A2 WO1994012219 A2 WO 1994012219A2 US 9311458 W US9311458 W US 9311458W WO 9412219 A2 WO9412219 A2 WO 9412219A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- igf
- mutein
- peg
- conjugate
- free cysteine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Definitions
- This invention relates to the modification of polypeptides, and more particularly to the modification of insulin-like growth factors and to methods of making and using such modified polypeptides.
- the insulin gene family comprised of insulin, relaxin, insulin-like growth factors 1 and 2, and possibly the beta subunit of 7S nerve growth factor, represents a group of structurally related polypeptides whose biological functions have diverged as reported in Dull, et al., Nature 310:777-781 ( 1984).
- Insulin-like growth factors 1 and 2 are about 7-8 kilodalton proteins that are structurally related to each other and to insulin. IGF-1 and IGF-2 share about 70% amino acid identity with each other and about 30% amino acid identity with insulin. IGF-1 and IGF-2 are believed to have related tertiary structures as reported in PCT Application Publication No. WO 90/00569, published on January 25, 1990. The structural similarity between IGF-1 and IGF- 2 permits both to bind to IGF receptors. Two IGF receptors are known to exist. IGF-1 and IGF-2 bind to the IGF type I receptor, while insulin binds with less affinity to this receptor.
- the type I receptor preferentially binds IGF-1 and is believed to transduce the mitogenic effects of IGF-1 and IGF-2.
- IGF-2 binds to the type I receptor with a 10-fold lower affinity than IGF-1 .
- the second or type II IGF receptor preferentially binds IGF-2. Receptor binding is believed to be necessary for the biological activities of IGF-1 and IGF-2.
- IGF-1 and IGF-2 are mitogenic for a large number of cell types, including fibroblasts, keratinocytes, endothelial cells and osteoblasts (bone-forming cells) .
- IGF-1 and IGF-2 also stimulate differentiation of many cell types, e.g., synthesis and secretion of collagens by osteoblasts. IGF-1 and IGF-2 exert their mitogenic and cell differentiating effects by binding to the specific IGF cell surface receptors. IGF-1 also has been shown to inhibit protein catabolism in vivo, stimulate glucose uptake by cells and to promote survival of isolated neurons in culture. These properties have led to IGF-1 being tested as a therapeutic agent ⁇ for a variety of disease indications as reported in Froesch et al., Trends in Endocrinology and Metabolism, 254-260 (May/June 1990) and Cotterill, Clinical Endocrinology. 37: 1 1 -1 6 (1 992).
- IGFBP-1 through IGFBP-6 IGF binding proteins that circulate throughout the body. These proteins bind IGF-1 and IGF-2 with high affinity. The binding of IGF- 1 and IGF-2 to binding proteins reduces the action of these IGFs on cells by preventing their interaction with cell surface IGF receptors. IGF binding proteins, particularly IGFBP-3, also function to prolong the circulating half-lives of IGF-1 and IGF-2 in the blood stream. In the absence of IGF binding proteins, the half- life of IGF-1 in blood is less than 10 minutes. In contrast, when IGF-1 is bound to IGFBP-3, its half-life in blood is lengthened to about 8 hours.
- the circulating half-life of IGF-1 bound to the other smaller binding proteins is about 30 minutes as reported in Davis et al., J. of Endocrinology. 123:469-475 ( 1 989); Guler et al., Acta Endocrinolooica, 1 21 :753-758 (1989); and Hodgkinson et al., J. of
- IGF insulin growth factor
- binding proteins When IGF is bound to binding proteins, it is unable to bind to the IGF receptors and is therefore, no longer active in the body. Decreased affinity to binding proteins allows more of the IGF to be active in the body. Situations where this decreased affinity to binding proteins may be useful include, for example, cachexia, osteoporosis, and peripheral neuropathies.
- IGF binding proteins can vary greatly, depending upon the disease state. For example, IGFBP-1 levels are very high in diabetes patients, whereas they are nearly undetectable in normal patients as reported in Brismar et al., J. of Endocrinological Investigation, 1 1 :599-602 ( 1 988); Suikkari et al.. J. of Clinical Endocrinology and Metabolism. 66:266-273 ( 1 988); and Unterman et al., Biochem. Biophys. Res. Comm., 1 63:882-887 (1989). IGFBP-3 levels are reduced in severely ill patients such as those that have undergone major surgery as reported in Davies et al., J. Endocrinology,
- IGF-1 Insulin-like growth factor 1
- somatomedin C Insulin-like growth factor 1
- IGF-1 or IGF-1 having a deletion of the first three amino acids ordinarily found in IGF-1 were demonstrated in Tomas et al., Biochem. J., 276:547-554 (1991 ). Growth restoration in insulin- deficient diabetic rats by administration of recombinantly produced human IGF-1 is reported in Scheiwiller et al., Nature, 323: 169 (1986). IGF-1 and (des1 -3)IGF- 1 enhance growth in rats after gut resection, as reported in Lemmey et al., Am.
- IGF-1 and (des1 -3) IGF-1 are limited by their short circulating half-lives to situations when the proteins can be administered by continual infusion or by multiple daily injections to achieve their maximum therapeutic potential.
- Woodall et al., Horm. Metab. Res. , 23: 581 -584 (1991 ) reports that the same total dose of IGF-1 administered four times daily by subcutaneous injection was far superior in stimulating growth in mutant lit/lit mice (growth hormone deficient mice) than was the same total dose administered once daily.
- IGF-1 insulin growth factor-1
- injectable drugs patient compliance is expected to be higher for drugs that can be administered once a day rather than several times a day.
- IGF-1 In order for IGF-1 to be therapeutically effective when given once a day or once every few days, methods must be developed to increase its circulating half-life.
- Increasing the molecular weight of a protein by covalently bonding an inert polymer chain such as polyethylene glycol (PEG) to the protein is known to increase the circulating half-life of the protein in the body.
- PEG polyethylene glycol
- the present invention satisfies this need by increasing the molecular weight of the IGF. This is accomplished by providing site directed attachment of PEG to IGF.
- the invention relates to various modified forms of IGF.
- One type of modified IGF referred to as muteins, is produced by replacing cysteine residues for specific amino acids in the wild type molecule, or by inserting cysteine residues between amino acids in the wild type molecule. Cysteine residues which are not involved in intramolecular disulfide bonds are considered to be "free” .
- the free cysteine residues can be substituted or inserted in regions of the IGF molecule that are exposed on the protein's surface.
- the free cysteine serves as the attachment site for the polyethylene glycol (PEG) molecules to IGF, resulting in pegylated molecules. Attachment of the PEG molecule to a mutein creates a further modified form of IGF, or IGF-PEG conjugate of defined structure, where the PEG is attached to the IGF at a predetermined site.
- the present invention is directed to a polyethylene glycol (PEG) conjugate comprising PEG and a mutein of IGF, and particularly IGF-1 , where the PEG is attached to the mutein at a free cysteine in the N-terminal region of the mutein.
- PEG can be attached to the free cysteine through an activating group selected from maleimide, sulfhydryl, thiol, triflate, tresylate, aziridine, exirane and
- a suitable PEG can have a molecular weight of 5 kDa, 8.5 kDa, 10 kDa or 20 kDa.
- the PEG conjugate of the present invention can also contain a second protein to form a dumbbell.
- PEG conjugates are also provided.
- IGF-PEG conjugate when compared to wild type IGF, exhibits decreased affinity to binding proteins without significantly reduced biological activity.
- IGF can be administered to patients less frequently with equal or better effectiveness than in the past.
- the present invention is further directed to muteins of IGF having a free cysteine in the N-terminal region of the mutein.
- the muteins can be produced by recombinant methods.
- pharmaceutical compositions comprising the IGF-PEG conjugate and methods of using the IGF-PEG conjugate to treat a patient having or potentially having an IGF associated condition.
- the present invention is directed to modified forms of insulin-like growth factors (IGF) that provide beneficial properties not exhibited by wild-type IGF.
- the modified forms of IGF include muteins of these growth factors, containing at least one free cysteine. Conjugates containing the IGF muteins attached to polyethylene glycol (PEG) are also considered modified forms of IGF.
- PEG polyethylene glycol
- IGF refers to any polypeptide that binds to the IGF type I Receptor, including, for example, IGF-1 , IGF-2, (des1 -3)IGF-1 , and insulin. This hormone family is described in Blundell and Humbel, Nature, 287:781 -787
- wild type IGF-1 refers to the unmodified or naturally-occurring 70 amino acid form of IGF-1 . This term is used interchangeably with “IGF-1 " and
- IGF-PEG conjugate refers to an IGF molecule attached to a polyethylene glycol molecule. This is also referred to as a "Peg conjugate”.
- N-terminal region refers to approximately the first twenty amino acids from the N-terminus of IGF or an IGF mutein, and up to twelve amino acids preceding the first amino acid of the N-terminus of IGF.
- N-terminus refers to the first amino acid at the N-terminal region in the sequence of wild-type IGF, for example, glycine in IGF-1 .
- mutant refers to a modified form of IGF, which has been modified to contain a free cysteine in the N-terminal region.
- activating group refers to a site on the PEG molecule which attaches to the mutein.
- the term "pharmaceutically acceptable carrier” refers to a physiologically- compatible, aqueous or non-aqueous solvent.
- free cysteine refers to any cysteine residue not involved in an intramolecular disulfide bond.
- IGF associated condition refers to an existing or potential adverse physiological condition which results from an over-production or underproduction of IGF, IGF binding protein or IGF receptor, inappropriate or inadequate binding of IGF to binding proteins or receptors and any disease in which IGF administration alleviates disease symptoms.
- An IGF associated condition also refers to a condition in which administration of IGF to a normal patient has a desired effect.
- the term "patient” refers to any human or animal in need of treatment for an IGF associated condition.
- the IGF muteins of the present invention are produced by modifying wild- type IGF, particularly at the N- terminal region of the protein. Such modifications can be substitutions or additions of at least one cysteine residue in the N-terminal region of IGF.
- An IGF mutein can be produced by replacing a specific amino acid with a cysteine in approximately the first twenty amino acids of the N-terminus of wild-type IGF, such as, for example, substituting one of the first three amino acids of IGF-1 with a cysteine residue.
- the IGF muteins of the present invention can be produced by adding at least one cysteine residue in front of the first amino acid of IGF.
- a cysteine residue can be inserted in front of and adjacent to the first amino acid of IGF.
- the free cysteine can appear between Met and the first amino acid of IGF.
- a free cysteine residue can also appear in a group of about twelve or less amino acids inserted before the first amino acid of IGF to form a longer IGF mutein.
- the free cysteine residues are located in regions of the IGF-1 molecule exposed to the protein's surface.
- the N-terminal region is involved in the binding of the IGF to binding proteins, but is not involved in binding of IGF to cell surface IGF receptors.
- a mutein is referred to as "a cysteine mutein of IGF-1."
- the free cysteine residue acts as the attachment site for covalent linkage of the activating group on the polyethylene glycol.
- the newly created molecule comprising the cysteine mutein of IGF with the PEG attached is referred to as a "PEG conjugate of IGF” .
- the IGF muteins of the present invention can be prepared by methods well known to one skilled in the art. Such methods include mutagenic techniques for replacement or insertion of an amino acid residue, as described, for example, in
- the muteins produced by mutagenic techniques can then be expressed as recombinant products according to procedures known to those skilled in the art.
- the muteins can alternatively be synthesized by conventional methods known in the art.
- the IGF muteins can also be prepared according to the methods and techniques described in the examples set forth below.
- the present invention also provides IGF-PEG conjugates and methods of making such conjugates by attaching the IGF muteins to polyethylene glycol to increase the circulating half-life of the molecule in the body as well as decrease its affinity to IGF binding proteins.
- long chain polymer units of polyethylene glycol are bonded to the mutein via a covalent attachment to the sulfhydryl group of a free cysteine residue on the IGF mutein.
- PEG polyethylene glycol
- Various PEG polymers with different molecular weights, 5.0 kDa (PEG 5000 ), 8.5 kDa (PEG 8500 h 10 kDa (PEG 10 000 ), and 20 kDa (PEG 20 .ooo. can be usec - t0 make the IGF-PEG conjugates.
- the functional or reactive group attached to the long chain polyethylene glycol polymer is the activating group to which the IGF mutein attaches at the free cysteine site.
- Useful activating groups include, for example, maleimide, sulfhydryl, thiol, triflate, tresylate, aziridine, exirane, or 5-pyridyl.
- polyethylene glycol (PEG) polymers containing two activating groups can be used to create "dumbbell” type molecules containing two IGF muteins attached to one molecule of PEG at each end of the PEG molecule.
- PEG bis-malemide a polyethylene glycol polymer containing a maleimide activating group on each end of the PEG molecule
- dumbbell molecules can also comprise a single IGF mutein covalently attached via PEG to a second protein or peptide of different structure.
- the second protein or peptide can be, for example, a growth factor such as platelet-derived growth factor, or fibroblast growth factor.
- IGF-PEG mono-pegylated IGF-1
- dumbbell IGF-1 IGF-PEG-IGF
- the present invention further provides a pharmaceutical composition containing the IGF-PEG conjugates in a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier is physiological saline solution.
- Other pharmaceutically acceptable carriers can also be used.
- the carrier and the carrier are physiological saline solution.
- IGF-1 constitute a physiologically-compatible, slow-release formulation.
- the primary solvent in such a carrier may be either aqueous or non-aqueous in nature.
- the carrier may contain other pharmacologically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation.
- the carrier may contain still other pharmacologically-acceptable excipients for modifying or maintaining the stability, rate of dissolution, release, or absorption of the IGF-1 .
- excipients are those substances usually and customarily employed to formulate dosages for parenteral administration in either unit dose or multi-dose form.
- the pharmaceutical composition may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder.
- Such formulations may be stored either in a ready to use form or requiring reconstitution immediately prior to administration.
- the storage of such formulations can be at temperatures at least as low as 4°C and preferably at -70°C.
- Formulations containing IGF-1 can also be stored and administered at or near physiological pH. It is presently believed that storage and administration in a formulation at a high pH (i.e. greater than 8) or at a low pH (i.e. less than 5) is undesirable.
- the pharmaceutical composition of the present invention can be used to treat a patient having or potentially having an IGF associated condition.
- Some of these conditions may include, for example, dwarfism, diabetes, periodontal disease and osteoporosis.
- the pharmaceutical composition of the present invention can also be used to treat a condition in which administration of IGF to a normal patient has a desired effect; for example, using IGF-1 to enhance growth of a patient of normal stature.
- the manner of administering the formulations containing the IGF-PEG conjugate can be via an intraarticular, subcutaneous, intramuscular or intravenous injection, suppositories, enema, inhaled aerosol, or oral or topical routes.
- intraarticular, subcutaneous, intramuscular or intravenous injection, suppositories, enema, inhaled aerosol, or oral or topical routes may be administered.
- repeated subcutaneous or intramuscular injections may be administered. Both of these methods are intended to create a preselected concentration range of IGF-1 mutein in the patient's blood stream. It is believed that the maintenance of circulating concentrations of IGF-1 mutein of less than 0.01 ng per ml of plasma may not be effective, while the prolonged maintenance of circulating levels in excess of 100 ug per ml may be undesirable.
- the frequency of dosing will depend on pharmacokinetic parameters of the IGF-PEG conjugate in the formulation used.
- the IGF-1 gene was assembled in two stages. Initially, the DNA sequence encoding IGF-1 was joined to DNA sequences encoding the secretory leader sequence of the E. coli OMP A protein (ompAL). This gene fusion was constructed in order to determine whether IGF-1 could be efficiently secreted from E. coli. A second construct, in which IGF-1 is expressed as an intracellular protein in E. coli, was created by deleting DNA sequences encoding the OmpA leader sequence and replacing them with DNA sequences that allow intracellular expression of IGF-1 . B. Construction of the OmpAL-IGF-1 gene fusion
- OmpAI U SEQ ID NO:2
- OmpA2U SEQ ID NO:3
- OmpAI L SEQ ID N0:4
- OmpA2L SEQ ID NO:5
- This DNA fragment was mixed with BamHI + Pstl-digested PUC18 DNA (commercially available from Boehringer Mannhein Biochemicals, Indianapolis, IN) and the two synthetic oligonucleotides [IGF-1 (1 -14) U + L] (SEQ ID NO:6 and SEQ ID NO:7) were ligated together.
- the . ligation mixture was used to transform E. coli strain JM109 (commercially available from New England Biolabs, Beverly, MA) and individual colonies isolated.
- These plasmids (OmpALIGF-1 pUC18) have a translational start signal followed by DNA sequences encoding the OmpA signal sequence and the first 14 amino acids of IGF-1 .
- the BamHI/Hindlll fragment containing the OmpAL-IGF-1 gene fusion described above was purified from plasmid pT3XI-2 ⁇ 10C(TC3)ompALIGF-1 and digested with Hinfl.
- the approximate 200 bp Hinfl/Hindlll DNA fragment was mixed with the annealed, complementary synthetic oligonucleotides (MetlGFI U).
- DNA fragment containing the mutant IGF-1 gene was purified and cloned into the BamHI and Hindlll sites of plasmid M13 mp19.
- Uracil-containing single-stranded template DNA was prepared following propagation of the phage in E. coli strain CJ236 (supplied with Muta-Gene Kit purchased from Bio-Rad Laboratories, Richmond, CA).
- the oligonucleotide used for mutagenesis had the sequence: 5' - GATGATTAAATGGGTCCGGAGACT - 3' (SEQ ID NO 1 2).
- the mutagenesis reaction product was used to transform E. coli strain JM109 and individual plaques picked.
- Double-stranded replicative form DNA from individual phages was isolated, digested with BamHI + Hindlll and the _200 bp fragment containing the IGF-1 gene purified.
- the purified DNA was cloned into the BamHI + Hindlll generated site of plasmid pT5T and used to transform E. coli strain BL21 /DE3.
- One bacterial colony with the correct plasmid was named ⁇ 10(TC3)mutlGF-1 pT5T.
- isolates were sequenced, and all were correct.
- EXAMPLE 2 Construction of IGF-1 Muteins
- Four muteins of IGF-1 were constructed. Three of the muteins replaced each of the first three amino acids of IGF-1 with a cysteine residue. These muteins are referred to as C1 , C2, and C3, respectively.
- the fourth mutein introduced a cysteine residue between the N-terminal methionine residue and the first amino acid of IGF-1 . This mutein is referred to as -1 C.
- the muteins of IGF-1 were made using the polymerase chain reaction (PCR) technique as described below.
- the starting plasmid used for the mutagenesis experiments was ⁇ 10(TC3)mutlGF-1 pT5T, which is described in Example 1 .
- This plasmid contains DNA sequences encoding an initiator methionine followed by the sequence of the natural human IGF-1 protein. Mutant IGF-1 DNA sequences were amplified from this gene using a 5' mutagenesis oligonucleotide that contained the desired mutation and a 3' oligonucleotide of correct sequence. The 5' mutagenesis oligonucleotides were designed so that they incorporated the first methionine of the gene as part of an Nde I restriction enzyme cleavage site (CATATG).
- CAATG Nde I restriction enzyme cleavage site
- Each mutagenesis oligonucleotide contained the desired mutation followed by 1 5 to 21 nucleotides that were a perfect match to the IGF-1 gene sequences in plasmid ⁇ 10(TC3)mutlGF-1 pT5T.
- the 3' oligonucleotide was 25 nucleotides long and was designed to encode the last 6 codons of IGF-1 and to contain the Hind III site that follows the stop codon.
- Plasmid pT5T is described in Example 1 .
- the ligation reactions were used to transform E. coli strain BL21 /DE3 and colonies selected on LB agar plates containing 50ug/ml of ampicillin.
- Mini plasmid DNA preps were made from several colonies from the transformation plates.
- the DNAs were digested with Eco RV and Hind III to determine which transformants contained IGF-1 DNA inserts. Plasmids containing
- IGF-1 DNA inserts were sequenced to verify that the inserts were correctly mutated (the entire IGF gene was sequenced for each mutein).
- Isopropyl-beta-D-thiogalactopyranoside IPTG was added to 1 mM to induce expression of T7 polymerase and the subsequent transcription and translation of the IGF muteins.
- IPTG Isopropyl-beta-D-thiogalactopyranoside
- Approximately 0.1 OD unit of cells were lysed in SDS sample buffer by boiling for two minutes and electrophoresed on a 1 6% polyacrylamide SDS gel. The gel was stained with Coomassie blue.
- IGF-1 protein bands of the expected size which is approximately 7-8 kDa. were observed in the lanes loaded with induced cells for each mutein as well as for the wild-type control.
- E. coli cells expressing the IGF-1 C3 mutein were suspended in Buffer A (50 mM Tris, pH 7.5, 20 mM NaCI and 1 mM dithiothreitol (DTT) at a concentration of 40 ml Buffer A to 10 g cell paste, and disrupted at 1 800 psi using a French pressure cell (SLM Instruments, Inc., Urbana IL).
- the suspension was centrifuged at 20,000 X g for 30 min, and aliquots of the pellet and supernatant analyzed by SDS-PAGE. A major band corresponding to the IGF-1 C3 mutein was present in the pellet, but not the supernatant.
- the pellet was suspended in Buffer A at a concentration of 40 ml Buffer A to 10 g cell paste, and re-centrifuged at 20,000 X g for 30 min. This wash procedure was repeated
- the final pellet containing the IGF-1 C3 mutein was suspended in 6 M guanidine, 50 mM Tris, pH 7.5, 6 mM DTT at a concentration of 25 ml to 10 g cells using a ground glass homogenizer. The suspension was incubated at room temperature for 1 5 min. The undissolved protein was removed by centrifugation at 20,000 X g for 30 min. The final concentration of the C3 mutein was 1 .0 mg/ml. SDS-PAGE analysis of the pellet and supernatant following the procedure of Example 2 showed that IGF-1 C3 mutein was present in the supernatant only. The denatured and reduced IGF-1 mutein was subjected to the following three-step refolding procedure:
- Refold mixtures (435 ml) prepared from 20g of E. coli paste containing either the refolded C3 or C2 mutein of Example 3 were concentrated to 100ml, acidified to pH 5.5 with 5M HCI, dialyzed against 20 mM sodium acetate, pH 5.5, and loaded onto an S-Sepharose (Pharmacia/LKB, Piscataway, NJ) column (1 .6 X 1 5 cm) previously equilibrated with the sodium acetate buffer described above. The bound protein was eluted with a 300 ml linear gradient from 0 to 0.5M NaCI. Three ml fractions were collected. A single major protein peak eluted at 0.2-0.3M NaCI. Aliquots ( 100 ul and 25 ul) of each peak were analyzed separately by reverse phase (RP-4 1 X 250 mm) and gel filtration chromatography (Superdex
- the protein was eluted at 2.0 ml/min, and aliquots (1 Oul) of each fraction were analyzed by RP-4 reverse phase chromatography and SDS-PAGE following the procedure of Example 2. Fractions containing correctly refolded IGF-1 C3 or IGF-1 C2 mutein monomer of 95 % or more purity were pooled and concentrated to 250 ug/ml.
- This material was assayed for bioactivity and reacted with an 8.5 kDa polyethylene glycol as described below.
- the partially reduced IGF-1 mutein was reacted with either the 8.5 kDa PEG or the 20 kDa PEG in a 20 ml reaction mixture containing 2.3 mg (296 nmoles) of protein, 9.985 mg (1 1 74 nmoles) 8.5 kDa PEG in 1 5 mM sodium acetate, 26 mM sodium phosphate, pH 7.0.
- the final concentration of protein was 1 12 mg/l, and the molar ratio of 8.5 kDa PEG:protein was 4: 1 .
- the reaction mixture was incubated at room temperature for 3 hours, and terminated by placing at 4oC or freezing at -20°C.
- rlGF-1 human metlGF-1
- IGF-BP1 insulin-like growth factor binding protein 1
- IGF-1 by measuring the relative amount of 3 H-thymidine incorporated into rat osteosarcoma cells when varying amounts of the proteins were present under serum free conditions.
- the rat osteosarcoma cells (the UMR106 cell line; obtained from American Type Culture Collection, Accession No. CRL-1 661 , Rockville, Maryland) were plated at 5-6 X 104 cells in 0.5 ml of Ham's F1 2 Media
- the ED50 (dose required for half maximal activity) of recombinant IGF-1 was 5-10 ng/ml compared with 30-40 ng/ml for unpegylated C3 and C2 muteins, and the pegylated C3 and C2 muteins.
- the relative affinities of the C3 and C2 muteins and the pegylated C3 and C2 muteins for IGF binding protein-1 were compared to that of the wild type IGF-1 by measuring the ability of IGF-BP1 to inhibit the mitogenic activities of the proteins on rat osteosarcoma cells.
- the rat UMR106 osteosarcoma cells were plated at 5-6 X 104 cells in 0.5 ml of Ham's F12 containing 7% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin and 2 mM L-glutamine per well in 48-well tissue culture plates.
- the cells were washed twice with PBS and pre- incubated in serum-free Ham's F12 medium containing 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine for 24 hours.
- serum-free Ham's F12 medium containing 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine for 24 hours.
- 0.5 ml of F12 serum-free medium containing either 50 ng/ml or 200ng/ml of rlGF-1 , C3 or C2 mutein, or pegylated C3 or C2 mutein were incubated separately with varying amounts of IGF-BP1 (100 ng/ml - 1 X 104 ng/ml) for an additional 20-24 hours.
- pegylated C3 mutein has greatly reduced affinity for IGFBP1 when compared to IGF-1 .
- the mitogenic activity of the pegylated C3 mutein will not be inhibited by IGF binding proteins under conditions where the mitogenic activity of IGF-1 will be inhibited.
- the affinity of pegylated C2 mutein for IGFBP1 is the same as the affinity of wild type IGF-1 .
- the mitogenic activity of pegylated C2 mutein will be inhibited by IGF binding proteins under the same conditions where the mitogenic activity of IGF-1 will be inhibited.
- mice Male Sprague Dawley rats with pituitary glands surgically removed (hypophysectomized or Hypox rats) and weighing 1 10-1 21 grams were obtained from Charles River Co. The rats were maintained in cages with lighting controlled over a 12 h-light/12 h-dark cycle.
- the animals had continuous access to water and food. Five animals were housed per cage. The weights of the rats were monitored daily and only rats with weight gains of less than 2 grams per week during the 2-3 weeks after arrival were considered to be successivefully hypophysectomized and used for the experiments.
- mice (10 Hypox rats per group) were injected every third day (ETD) subcutaneously (sc) with WT rIGF-l (1 60 mg, 320mg), unpegylated C2 (320mg), unpegylated C3 (320mg), pegylated C2 (C2-PEG, 320mg) or Pegylated C3 (C3-PEG,320mg) dissolved in 0.2 ml of binding buffer (0.1 M HEPES-0.05 M NaH 2 P0 4 ).
- a separate group of 10 animals received 0.2ml vehicle. Injections were given between 0700 hours and 0800 hours and body weights were recorded daily between 1600 h and 1700 h. The weights of rats on the day after the last injection were taken as the final weight.
- mice (9 Hypox rats per group) were injected every third day sub-cutaneously with WT rIGF-l (320mg, single injection daily, SID; 320mg ETD; 640mg ETD), or C3-PEG (320mg ETD, 640mg ETD, 960mg ETD). dissolved in 0.2 ml of binding buffer (0.1 M HEPES-0.05 M NaH 2 P0 4 ). A separate group of 9 animals received 0.2ml vehicle. Injections were given between 0700 h and
- mice (10 Hypox rats) were injected every third day sub-cutaneously with C3-PEG (160mg ETD, 320mg ETD), dissolved in 0.2 ml vehicle (0.1 M HEPES-0.05 M NaH 2 P0 4 ). A separate group of 10 animals received 0.2ml vehicle. Injections were given between 0700 h and 0800 h and body weight were recorded daily between 1600-1700 h. The weights of rats on the day after the last injection were taken as the final weight. At the end of Experiments I & II, rats were asphyxiated with C0 2 and weighed. In Experiment III, the tibia were removed and the epiphyseal width measured.
- IGF-I muteins with reduced affinity for IGF binding proteins exhibit greater in vivo bioactivity than WT-IGF-I.
- Un-PEGylated C2 has unaltered affinity for IGF-BP1 , and similar bioactivity to WT IGF-I.
- C3-PEG administered sc ETD exhibits greater potency than WT IGF-I administered sc ETD. All doses of C3-PEG stimulated greater mean weight gain than animals given 320mg WT IGF-I SID. The enhanced pharmacodynamics of C3-PEG make it more potent than WT IGF-I in the animal model described.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019950702108A KR950703999A (en) | 1992-11-25 | 1993-11-24 | MODIFIED INSULIN-LIKE GROWTH FACTORS |
EP94907044A EP0679095A1 (en) | 1992-11-25 | 1993-11-24 | Modified insulin-like growth factors |
AU60482/94A AU6048294A (en) | 1992-11-25 | 1993-11-24 | Modified insulin-like growth factors |
JP6513381A JPH08506095A (en) | 1992-11-25 | 1993-11-24 | Modified insulin-like growth factor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98051992A | 1992-11-25 | 1992-11-25 | |
US07/980,519 | 1992-11-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994012219A2 true WO1994012219A2 (en) | 1994-06-09 |
WO1994012219A3 WO1994012219A3 (en) | 1994-07-21 |
Family
ID=25527621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/011458 WO1994012219A2 (en) | 1992-11-25 | 1993-11-24 | Modified insulin-like growth factors |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0679095A1 (en) |
JP (1) | JPH08506095A (en) |
KR (1) | KR950703999A (en) |
AU (1) | AU6048294A (en) |
CA (1) | CA2149048A1 (en) |
WO (1) | WO1994012219A2 (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0668354A1 (en) * | 1989-04-21 | 1995-08-23 | Genetics Institute, Inc. | Cysteine added variants of G-CSF and chemical modifications thereof |
WO1995032003A1 (en) * | 1994-05-24 | 1995-11-30 | Amgen Boulder Inc. | Modified insulin-like growth factors |
WO2000042175A1 (en) | 1999-01-14 | 2000-07-20 | Bolder Biotechnology Inc. | Methods for making proteins containing free cysteine residues |
WO2001087925A2 (en) * | 2000-05-16 | 2001-11-22 | Bolder Biotechnology, Inc. | Methods for refolding proteins containing free cysteine residues |
US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
US6870033B1 (en) | 1997-02-21 | 2005-03-22 | Genentech, Inc. | Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies |
US7005504B2 (en) | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
EP1674113A1 (en) * | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
US7090835B2 (en) | 1994-10-12 | 2006-08-15 | Amgen, Inc. | N-terminally chemically modified protein compositions and methods |
US7141545B2 (en) | 1998-04-03 | 2006-11-28 | Novartis Vaccines And Diagnostics, Inc. | Compositions and methods for treating articular cartilage disorders |
US7148333B2 (en) * | 1997-07-14 | 2006-12-12 | Bolder Biotechnology, Inc. | Cysteine variants of granulocyte-macrophage colony-stimulating factor |
US7153943B2 (en) * | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
US7214776B2 (en) | 1999-01-21 | 2007-05-08 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US7270809B2 (en) | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
US7270972B1 (en) | 1999-04-02 | 2007-09-18 | Ajinomoto Co., Inc. | Process for producing subunit peptide originating in polymer protein |
US7399839B2 (en) | 1999-01-14 | 2008-07-15 | Bolder Biotechnology, Inc. | Monopegylated growth hormone proteins |
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
US7625996B2 (en) | 2006-08-31 | 2009-12-01 | Hoffmann-La Roche Inc. | Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol) |
EP2348043A1 (en) | 2001-10-02 | 2011-07-27 | Genentech, Inc. | APO-2 ligand variants and uses thereof |
WO2011098400A1 (en) * | 2010-02-11 | 2011-08-18 | F. Hoffmann-La Roche Ag | Igf-i poly (ethylene glycol) conjugates |
EP2500032A1 (en) | 2002-06-24 | 2012-09-19 | Genentech, Inc. | APO-2 ligand/trail variants and uses thereof |
US8329866B2 (en) | 2005-10-03 | 2012-12-11 | Bolder Biotechnology, Inc. | Long acting VEGF inhibitors and methods of use |
US8450459B2 (en) | 2003-10-10 | 2013-05-28 | Novo Nordisk A/S | IL-21 derivatives and variants |
US8475784B2 (en) | 2006-10-26 | 2013-07-02 | Novo Nordisk A/S | IL-21 variants |
US8552158B2 (en) | 2006-08-31 | 2013-10-08 | Hoffmann-La Roche Inc. | Method for the production of insulin-like growth factor-1 |
US8617531B2 (en) | 2006-12-14 | 2013-12-31 | Bolder Biotechnology, Inc. | Methods of making proteins and peptides containing a single free cysteine |
US8633300B2 (en) * | 2005-06-17 | 2014-01-21 | Novo Nordisk Healthcare Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
WO2017075173A2 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibodies and conjugates |
US10093978B2 (en) | 2013-08-12 | 2018-10-09 | Genentech, Inc. | Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms |
US10179821B2 (en) | 2014-05-01 | 2019-01-15 | Genentech, Inc. | Anti-factor D antibodies |
US10654932B2 (en) | 2015-10-30 | 2020-05-19 | Genentech, Inc. | Anti-factor D antibody variant conjugates and uses thereof |
WO2021194913A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Tie2-binding agents and methods of use |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US6309633B1 (en) * | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0458064A2 (en) * | 1990-05-04 | 1991-11-27 | American Cyanamid Company | Stabilization of somatotropins and other proteins by modification of cysteine residues |
US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
-
1993
- 1993-11-24 AU AU60482/94A patent/AU6048294A/en not_active Abandoned
- 1993-11-24 KR KR1019950702108A patent/KR950703999A/en not_active Application Discontinuation
- 1993-11-24 WO PCT/US1993/011458 patent/WO1994012219A2/en not_active Application Discontinuation
- 1993-11-24 JP JP6513381A patent/JPH08506095A/en active Pending
- 1993-11-24 EP EP94907044A patent/EP0679095A1/en not_active Withdrawn
- 1993-11-24 CA CA002149048A patent/CA2149048A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
EP0458064A2 (en) * | 1990-05-04 | 1991-11-27 | American Cyanamid Company | Stabilization of somatotropins and other proteins by modification of cysteine residues |
Non-Patent Citations (1)
Title |
---|
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US AN=79:197899 & BIOPOLYMERS, vol.18, no.2, 1979 pages 383 - 392 GLASS J D ET AL '4-PHENOXY-3,5-DINITROBENZOYL POLYETHYLENE GLYCOL REVERSIBLE ATTACHMENT OF CYSTEINE CONTAINING POLYPEPTIDES TO POLYMERS IN AQUEOUS SOLUTIONS.' * |
Cited By (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0668353A1 (en) * | 1989-04-21 | 1995-08-23 | Genetics Institute, Inc. | Cysteine added variants of EPO and chemical modifications thereof |
EP0668354A1 (en) * | 1989-04-21 | 1995-08-23 | Genetics Institute, Inc. | Cysteine added variants of G-CSF and chemical modifications thereof |
WO1995032003A1 (en) * | 1994-05-24 | 1995-11-30 | Amgen Boulder Inc. | Modified insulin-like growth factors |
US7090835B2 (en) | 1994-10-12 | 2006-08-15 | Amgen, Inc. | N-terminally chemically modified protein compositions and methods |
US6870033B1 (en) | 1997-02-21 | 2005-03-22 | Genentech, Inc. | Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies |
US7964184B2 (en) | 1997-07-14 | 2011-06-21 | Bolder Biotechnology, Inc. | Cysteine variants of interferon-gamma |
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
US7795396B2 (en) | 1997-07-14 | 2010-09-14 | Bolder Biotechnology, Inc. | COOH-terminally added cysteine variant of the beta interferon |
US9637530B2 (en) | 1997-07-14 | 2017-05-02 | Bolder Biotechnology, Inc. | Methods of preparing cysteine variants of human recombinant IL-11 |
US7560101B2 (en) | 1997-07-14 | 2009-07-14 | Bolder Biotechnology, Inc. | Method of treatment of an infection in an animal with GM-CSF cysteine muteins in the proximal region to helix A |
US8748392B2 (en) | 1997-07-14 | 2014-06-10 | Bolder Biotechnology Inc. | Methods of treatment using cysteine variants of interleukin-11 |
US10329337B2 (en) | 1997-07-14 | 2019-06-25 | Bolder Biotechnology, Inc. | Method to increase the number of circulating platelets by administering PEGylated cysteine variants of IL-11 |
US7824669B2 (en) | 1997-07-14 | 2010-11-02 | Bolder Biotechnology, Inc. | In vivo stimulation of peripheral blood progenitor cells by granulocyte-macrophage colony stimulating factor (GM-CSF) cysteine muteins and their PEGylated variants |
US7959909B2 (en) | 1997-07-14 | 2011-06-14 | Bolder Biotechnology, Inc. | Cysteine variants of interferon gamma |
US7148333B2 (en) * | 1997-07-14 | 2006-12-12 | Bolder Biotechnology, Inc. | Cysteine variants of granulocyte-macrophage colony-stimulating factor |
US7153943B2 (en) * | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
US8618256B2 (en) | 1997-07-14 | 2013-12-31 | Bolder Biotechnology | Cysteine variants of interferon gamma |
US8148500B2 (en) | 1997-07-14 | 2012-04-03 | Bolder Biotechnology, Inc. | Method of preparing cysteine mutants of human recombinant GM-CSF |
US8133480B2 (en) | 1997-07-14 | 2012-03-13 | Bolder Biotechnology, Inc. | Cysteine variants of interleukin-11 |
US7253267B2 (en) | 1997-07-14 | 2007-08-07 | Bolder Biotechnology Inc. | Cysteine variants of interleukin-11 |
US7270809B2 (en) | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
US7732572B2 (en) | 1997-07-14 | 2010-06-08 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
US7005504B2 (en) | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
US7141545B2 (en) | 1998-04-03 | 2006-11-28 | Novartis Vaccines And Diagnostics, Inc. | Compositions and methods for treating articular cartilage disorders |
US7399839B2 (en) | 1999-01-14 | 2008-07-15 | Bolder Biotechnology, Inc. | Monopegylated growth hormone proteins |
EP2305804A1 (en) | 1999-01-14 | 2011-04-06 | Bolder Biotechnology, Inc. | MonoPEGylated human growth hormone |
WO2000042175A1 (en) | 1999-01-14 | 2000-07-20 | Bolder Biotechnology Inc. | Methods for making proteins containing free cysteine residues |
US7629314B2 (en) | 1999-01-14 | 2009-12-08 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US8652468B2 (en) | 1999-01-21 | 2014-02-18 | Genentech, Inc. | Methods of binding TNF-α using anti-TNF-α antibody fragment-polymer conjugates |
US7507405B2 (en) | 1999-01-21 | 2009-03-24 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US7842789B2 (en) | 1999-01-21 | 2010-11-30 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US8147830B2 (en) | 1999-01-21 | 2012-04-03 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US7214776B2 (en) | 1999-01-21 | 2007-05-08 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US7270972B1 (en) | 1999-04-02 | 2007-09-18 | Ajinomoto Co., Inc. | Process for producing subunit peptide originating in polymer protein |
US8932828B2 (en) | 2000-05-16 | 2015-01-13 | Bolder Biotechnology, Inc. | Method for preparing recombinant granulocyte colony stimulating factor cysteine muteins |
WO2001087925A2 (en) * | 2000-05-16 | 2001-11-22 | Bolder Biotechnology, Inc. | Methods for refolding proteins containing free cysteine residues |
US7306931B2 (en) | 2000-05-16 | 2007-12-11 | Bolder Biotechnology, Inc. | Method for refolding proteins containing free cysteine residues |
CN1318443C (en) * | 2000-05-16 | 2007-05-30 | 博尔德生物技术公司 | Methods for refolding proteins containing free cysteine residues |
WO2001087925A3 (en) * | 2000-05-16 | 2002-08-01 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
EP2348043A1 (en) | 2001-10-02 | 2011-07-27 | Genentech, Inc. | APO-2 ligand variants and uses thereof |
EP2500032A1 (en) | 2002-06-24 | 2012-09-19 | Genentech, Inc. | APO-2 ligand/trail variants and uses thereof |
US8450459B2 (en) | 2003-10-10 | 2013-05-28 | Novo Nordisk A/S | IL-21 derivatives and variants |
US9724425B2 (en) | 2004-12-22 | 2017-08-08 | Hoffmann-La Roche Inc. | Conjugates of insulin-like growth factor-1 and poly(ethylene glycol) |
WO2006066891A3 (en) * | 2004-12-22 | 2007-05-31 | Hoffmann La Roche | Conjugates of insulin-like growth factor-1 (igf-1) and poly(ethylene glycol) |
WO2006066891A2 (en) * | 2004-12-22 | 2006-06-29 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (igf-1) and poly(ethylene glycol) |
EP1674113A1 (en) * | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
EA011284B1 (en) * | 2004-12-22 | 2009-02-27 | Ф.Хоффманн-Ля Рош Аг | Conjugates of insulin-like growth factor-1 (igf-1) and poly(ethylene glycol) |
US8633300B2 (en) * | 2005-06-17 | 2014-01-21 | Novo Nordisk Healthcare Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
US8329866B2 (en) | 2005-10-03 | 2012-12-11 | Bolder Biotechnology, Inc. | Long acting VEGF inhibitors and methods of use |
US8476232B2 (en) | 2006-08-31 | 2013-07-02 | Hoffman-La Roche Inc. | Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol) |
US8552158B2 (en) | 2006-08-31 | 2013-10-08 | Hoffmann-La Roche Inc. | Method for the production of insulin-like growth factor-1 |
US7625996B2 (en) | 2006-08-31 | 2009-12-01 | Hoffmann-La Roche Inc. | Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol) |
US8475784B2 (en) | 2006-10-26 | 2013-07-02 | Novo Nordisk A/S | IL-21 variants |
US8617531B2 (en) | 2006-12-14 | 2013-12-31 | Bolder Biotechnology, Inc. | Methods of making proteins and peptides containing a single free cysteine |
US10508131B2 (en) | 2006-12-14 | 2019-12-17 | Bolder Biotechnology, Inc. | Cysteine analogs of exendin-4 |
US9296804B2 (en) | 2006-12-14 | 2016-03-29 | Bolder Biotechnology, Inc. | NH2-terminal glutamine modified cysteine variants of interferon gamma |
WO2011098400A1 (en) * | 2010-02-11 | 2011-08-18 | F. Hoffmann-La Roche Ag | Igf-i poly (ethylene glycol) conjugates |
CN102740896A (en) * | 2010-02-11 | 2012-10-17 | 霍夫曼-拉罗奇有限公司 | Igf-i poly (ethylene glycol) conjugates |
US9587006B2 (en) | 2010-02-11 | 2017-03-07 | Hoffmann-La Roche Inc. | IGF-I poly (ethylene glycol) conjugates |
US10093978B2 (en) | 2013-08-12 | 2018-10-09 | Genentech, Inc. | Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms |
US10947591B2 (en) | 2013-08-12 | 2021-03-16 | Genentech, Inc. | Compositions and method for treating complement-associated conditions |
US10179821B2 (en) | 2014-05-01 | 2019-01-15 | Genentech, Inc. | Anti-factor D antibodies |
US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
WO2017075173A2 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibodies and conjugates |
US10654932B2 (en) | 2015-10-30 | 2020-05-19 | Genentech, Inc. | Anti-factor D antibody variant conjugates and uses thereof |
US10961313B2 (en) | 2015-10-30 | 2021-03-30 | Genentech, Inc. | Anti-factor D antibody variant conjugates and uses thereof |
WO2021194913A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Tie2-binding agents and methods of use |
Also Published As
Publication number | Publication date |
---|---|
KR950703999A (en) | 1995-11-17 |
AU6048294A (en) | 1994-06-22 |
CA2149048A1 (en) | 1994-06-09 |
JPH08506095A (en) | 1996-07-02 |
EP0679095A1 (en) | 1995-11-02 |
WO1994012219A3 (en) | 1994-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994012219A2 (en) | Modified insulin-like growth factors | |
EP0756494A1 (en) | Modified insulin-like growth factors | |
JP4949844B2 (en) | A novel peptide that binds to the erythropoietin receptor | |
US6703480B1 (en) | Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use | |
US6420339B1 (en) | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility | |
JP4266028B2 (en) | A novel peptide that binds to the erythropoietin receptor | |
JPS63500036A (en) | Fibroblast growth factor | |
JP5961730B2 (en) | Modified erythropoietin | |
JPH06228199A (en) | Peptide binding body capable of passing through blood brain barrier | |
JPH08301899A (en) | Igf-1 superagonist | |
WO1996033216A1 (en) | Truncated igf-i | |
WO1993019084A1 (en) | Refolding and purification of insulin-like growth factor i | |
KR19990022716A (en) | Bone stimulating factor | |
JP2007523840A (en) | Combined use of keratinocyte growth factor agonist and castrin compound | |
EA009289B1 (en) | THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β | |
JP2008519858A (en) | A novel peptide that binds to the erythropoietin receptor | |
AU6093794A (en) | Wound healing composition | |
US20090088374A1 (en) | Novel use | |
RU2119800C1 (en) | Growth hormone factor peptide analog and method and composition for stimulating growth hormone secretion | |
US20090042802A1 (en) | Compounds and peptides that bind the kgf receptor | |
WO2004005335A2 (en) | Multimerised growth hormone fusion proteins | |
JPH03180192A (en) | Production of human pro-tgf-beta1 by genetic recombination | |
US20090137465A1 (en) | Novel use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication | ||
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2149048 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994907044 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1994907044 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1995 448514 Country of ref document: US Date of ref document: 19951204 Kind code of ref document: A |
|
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication |
Free format text: AM+,KG+,MD+,TJ+,TM+ |
|
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) |
Free format text: AM*,KG*,MD*,TJ*,TM* |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994907044 Country of ref document: EP |